The Week

Brown & Brown (BRO) fell 7.32% over four trading days to close at $66.19. The S&P 500 lost 0.8% for the week, so the insurance broker underperformed the benchmark by about 6.52 percentage points. The move started with a gap down on Tuesday (Sep 8), opening at $70.03 and closing at $68.18. Wednesday and Thursday extended lower on shrinking volume, and Friday (Sep 11) touched a low of $65.41 before settling at $66.19. Weekly amplitude was 6.6%, with average daily volume around 1.81m shares, roughly 17% below the 60-day rolling median.

Key Events

The most company-specific item this week was Brown & Brown’s investor presentation on Sep 10, outlining 2025 results, liquidity and its growth strategy. On the same day, a separate piece grouped the company among nine niche assets in a discussion of unbundling the value chain, highlighting the niche character of its business model. A Sep 9 item noted Rep. April McClain Delaney’s sale of up to $7.43m of ITT stock, which has no direct business link to Brown & Brown. No material non-routine filings surfaced during the week. Overall, the news flow was light, and the price move reflected broad market weakness plus a low-volume pullback in the stock itself.

Analyst Ratings

Among 19 firms covering the stock, 2 rate it buy, 2 overweight, 14 neutral and 1 sell. The consensus rating is hold, with a consensus target of $76.6875, about 15.9% above the latest close of $66.19. Targets range from $60 to $90, a spread of roughly $30 that shows views on valuation remain divided. Within the insurance broker industry, the stock ranks 5th out of 25, placing it in the top 20% band.

The Week Ahead

Several US macro prints land next week: the Empire State manufacturing index on Tuesday (Sep 15), and on Wednesday (Sep 16) retail sales, retail sales ex-autos, import prices, the NAHB housing market index and EIA crude inventories. These will feed into rate expectations and risk appetite for rate-sensitive names like BRO. No company earnings are scheduled, though any follow-through on the growth strategy outlined in the investor presentation is worth tracking.

In Short

The week’s pullback came on light news: the stock fell on shrinking volume, the consensus rating stayed at hold, and valuation signals looked moderate at roughly 18.6x P/E and 1.76x P/B, with about 15.9% upside to the consensus target. On the latest trading day, mid- and small-lot flows were active in both directions, showing no clear tilt. The next watchpoints are how the macro data shapes pricing for rate-sensitive insurance brokers, and whether the company’s presentation translates into more concrete execution signals.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.